Rankings
▼
Calendar
CTNM FY 2021 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$504M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$29M
Net Income
-$29M
EPS (Diluted)
$-1.15
Cash Flow
Operating Cash Flow
-$26M
Free Cash Flow
-$26M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$71M
Total Liabilities
$9M
Stockholders' Equity
$62M
Cash & Equivalents
$5M
← FY 2022
All Quarters
